Brand Name: XBIRA 250 mg
Generic Name: Abiraterone Acetate
Manufacturer: Cipla Ltd., India
Strength: 250 mg
Dosage Form: Oral Tablets
Packaging: 120 Tablets per Bottle (as shown on the product packaging)
Therapeutic Category: Oncology / Prostate Cancer Treatment
Product Type: Prescription Medicine
Supplier & Exporter: BizHQ – India
Website: www.medicineindiaexport.com
Introduction to XBIRA 250 mg Tablets
XBIRA 250 mg Tablets contain Abiraterone Acetate, a prescription medicine used in the treatment of certain types of advanced prostate cancer. Manufactured by Cipla Ltd., XBIRA is part of a class of medicines known as androgen biosynthesis inhibitors.
BizHQ is an India-based pharmaceutical export business offering international buyers assistance with sourcing and procurement enquiries for oncology medicines, including XBIRA 250 mg Tablets, subject to product availability and applicable regulatory requirements.
We serve pharmaceutical importers, licensed wholesalers, distributors, hospitals, and authorized healthcare procurement organizations seeking medicines from India.
Product Specifications
| Product Details | Description |
|---|---|
| Product Name | XBIRA 250 mg |
| Active Ingredient | Abiraterone Acetate |
| Strength | 250 mg |
| Manufacturer | Cipla Ltd. |
| Country of Origin | India |
| Dosage Form | Tablets |
| Administration | Oral |
| Pack Size | 120 Tablets |
| Therapeutic Use | Advanced Prostate Cancer |
| Storage | Follow approved product labeling |
| Prescription Status | Prescription Only |
| Export Availability | Subject to stock and destination-country regulations |
What Is XBIRA 250 mg Used For?
XBIRA 250 mg contains Abiraterone Acetate, which reduces androgen production by inhibiting the CYP17 enzyme.
Androgens, including testosterone, can stimulate the growth of prostate cancer cells. By reducing androgen production, Abiraterone Acetate helps manage certain forms of advanced prostate cancer.
Depending on the approved indication and treatment regimen, Abiraterone Acetate may be prescribed for:
Metastatic castration-resistant prostate cancer (mCRPC).
Certain cases of metastatic hormone-sensitive prostate cancer (mHSPC).
Abiraterone is generally used with a corticosteroid such as prednisone or prednisolone, as directed by the treating oncologist. Patients typically also require continued medical or surgical castration.
Important: XBIRA must be used only under specialist medical supervision. The approved indications, dosing instructions, and required accompanying medicines should be confirmed against the relevant country-specific prescribing information.
Benefits of Sourcing XBIRA 250 mg from India
India is an important international pharmaceutical manufacturing and export market, supplying generic medicines to numerous countries.
International pharmaceutical buyers may consider Indian sourcing for several reasons:
1. Established Pharmaceutical Manufacturing
India has an extensive pharmaceutical manufacturing industry with experience producing prescription medicines, including oncology treatments.
2. Generic Medicine Sourcing
Indian pharmaceutical suppliers may offer access to generic oncology medicines, subject to regulatory approval, commercial availability, and destination-market requirements.
3. International Procurement Support
Experienced exporters can assist buyers with quotations, packaging information, manufacturer documentation, and shipping coordination.
4. Bulk Procurement Enquiries
Licensed pharmaceutical distributors and institutional purchasers can request quotations for commercial quantities, subject to stock, manufacturer distribution policies, and applicable law.
International Export Markets for XBIRA 250 mg
BizHQ welcomes procurement enquiries from authorized pharmaceutical buyers in international markets, including:
Asia: Malaysia, Philippines, Vietnam, Thailand, Singapore, South Korea, Japan, Nepal, Sri Lanka, and Bangladesh.
Middle East: United Arab Emirates, Saudi Arabia, Oman, Qatar, Kuwait, Bahrain, and Jordan.
Africa: South Africa, Kenya, Nigeria, Ghana, Uganda, Tanzania, Zambia, and Ethiopia.
Europe: United Kingdom, Germany, France, Italy, Spain, Netherlands, and Poland.
Americas: United States, Canada, Mexico, Brazil, Chile, and Peru.
Oceania: Australia and New Zealand.
These are potential enquiry markets, not a representation that XBIRA is registered, approved, or legally importable in every listed country. Shipment eligibility depends on local marketing authorization, import permits, prescription medicine rules, and applicable export controls.
Pharmaceutical Export Documentation
Depending on the destination country, product, shipment, and buyer requirements, international pharmaceutical procurement may involve:
Commercial invoice and packing list.
Certificate of Analysis (COA), where available and applicable.
Certificate of Origin (COO), when required.
Manufacturer and product registration documentation.
Applicable pharmaceutical export documentation.
Import license or authorization from the destination-country regulator.
Shipping and customs clearance documentation.
Documentation availability must be confirmed before order acceptance.
Storage and Handling
XBIRA 250 mg Tablets should be stored according to the manufacturer's approved packaging instructions.
For pharmaceutical importers and distributors, important handling considerations include maintaining appropriate storage conditions, protecting the packaging from damage, monitoring expiry dates, and ensuring batch traceability throughout distribution.
Frequently Asked Questions (FAQs)
Q1. What is XBIRA 250 mg?
XBIRA 250 mg is a prescription oncology medicine containing Abiraterone Acetate, manufactured by Cipla Ltd.
Q2. Who manufactures XBIRA 250 mg Tablets?
XBIRA is manufactured by Cipla Ltd., an Indian pharmaceutical company.
Q3. Can I enquire about wholesale quantities of XBIRA 250 mg?
Yes. Licensed pharmaceutical importers, wholesalers, and institutional procurement buyers can contact BizHQ for sourcing and quotation enquiries. Availability and order eligibility require confirmation.
Q4. Can XBIRA 250 mg be exported internationally?
International shipment may be possible where the product, buyer, supplier, and import arrangements comply with applicable regulations. Registration and import requirements vary by country.
Q5. What is the packaging size of XBIRA 250 mg?
The product packaging shown indicates 120 tablets per sealed container. Buyers should confirm the packaging configuration for the batch being offered.
Q6. What is the minimum order quantity (MOQ)?
The MOQ depends on available inventory, supplier requirements, and destination-market conditions. Contact BizHQ for a quotation.
Q7. Is XBIRA 250 mg available without a prescription?
XBIRA is a prescription medicine and should only be supplied through lawful, authorized channels.
Q8. Can international buyers request batch information?
Buyers may request available batch details, expiry information, and applicable quality documentation before confirming procurement.
Why Contact BizHQ for XBIRA 250 mg Sourcing?
BizHQ assists international pharmaceutical buyers with enquiries related to Indian pharmaceutical products.
Our business focuses on connecting eligible buyers with sourcing opportunities and supporting commercial communication regarding product specifications, quotations, packaging, and shipment requirements.
For XBIRA 250 mg procurement enquiries, buyers should provide their destination country, required quantity, and relevant import authorization details so that product availability and compliance requirements can be assessed.
Contact BizHQ – Pharmaceutical Export Enquiries
Business Name: BizHQ
Website: www.medicineindiaexport.com
Email: sales.medindiaexport@gmail.com
WhatsApp: +91 7218129896
Country: India
Request a quotation for XBIRA 250 mg Tablets (Abiraterone Acetate).
